1. A method for the selective treatment of a patient having psoriatic arthritis (PsA), comprising: a) selectively administering a therapeutically effective amount of an IL-17 antagonist to a patient based on the fact that the patient has an allele in the HLA-DRB1 * 04 allelic group, has an rs4263839 or does not have the rs240993 absence response allele; or b) selectively administering a therapeutically effective amount of another agent for treating PsA to a patient based on the fact that the patient does not have an rs240993 lack of allele, has an allele in the HLA-DRB1 * 04 allele group, or has an rs4263839.2 response allele. The method of claim 1, wherein the other agent for treating PsA is selected from the group consisting of NSAIDs, a TNF-alpha antagonist, sulfasalazine, methotrexate, a corticosteroid, and combinations thereof. A method for selectively treating a patient having PsA with an IL-17 antagonist, comprising: a) selecting a patient for treatment with an IL-17 antagonist based on the fact that the patient has an allele in the HLA-DRB1 * 04 allelic group, has an rs4263839 response allele, or does not have an allele lack of response rs240993; and b) then selectively administering a therapeutically effective amount of an IL-17 antagonist to the patient. The method of claim 3, further comprising: analyzing the biological sample from the patient for the presence of an allele in the HLA-DRB1 * 04 allele group, an rs4263839 response allele, or an rs240993 non-response allele, in which the analysis step is carried out prior to the selection step. The method of claim 4, wherein the analysis step comprises analyzing a biological sample for a product that is a nucleic acid, an allele in the HLA-DRB1 * 04 allele group, an rs4263839 response allele, or an rs240993 non-response allele, on an allele polypeptide product in the HLA-DRB1 allele group * 04, response allele rs4263839 or all�
展开▼
